Recent Updates
Recently added Catalysts
AYTU Positive Sentiment Score: 70/100

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Wednesday, January 28, 2026 2 min read
Key Takeaway: Aytu BioPharma will report its operational and financial results for the second quarter of fiscal 2026 on February 3, 2026. The company has scheduled a conference call and webcast for the same day to discuss these results. Interested parties can access the call through provided dial-in information and a webcast link.

Market Sentiment Analysis

POSITIVE FACTORS

  • Aytu BioPharma is advancing innovative medicines for CNS diseases.
  • The upcoming financial results may indicate positive growth.
  • The company is committed to optimal patient outcomes.

Full Press Release Details

DENVER, CO /ACCESS Newswire/ January 27, 2026 /Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its second quarter of fiscal 2026, after the market close on Tuesday, February 3, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, February 3, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.

Conference Call Details

Date and Time:Tuesday, February 3, 2026, at 4:30 p.m. Eastern time.

Call-in Information:Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 567381.
Webcast Information:The webcast will be accessible live and archived athttps://www.webcaster5.com/Webcast/Page/2142/53322, and accessible on the Investors section of the Company's website athttps://investors.aytubio.com/under Events & Presentations.
Replay:A teleconference replay of the call will be available until February 17, 2026, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53322.

About Aytu BioPharma

Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visitaytubio.comor follow us onLinkedIn.

Contacts for Investors

Ryan Selhorn, Chief Financial OfficerAytu BioPharma, Inc.rselhorn@aytubio.com
Robert BlumLytham Partnersaytu@lythampartners.com

SOURCE:Aytu BioPharma, Inc.

Frequently Asked Questions

When will Aytu BioPharma report its Q2 results?

Aytu BioPharma will report its Q2 results on February 3, 2026.

What time is the conference call for Q2 results?

The conference call is scheduled for 4:30 p.m. Eastern time on February 3, 2026.

How can I access the conference call?

You can access the call by dialing (888) 506-0062 for U.S. callers.

Is there a webcast available for the Q2 results?

Yes, a webcast will be available live and archived on Aytu's website.

What products does Aytu BioPharma focus on?

Aytu focuses on innovative medicines for CNS diseases, including treatments for MDD and ADHD.

Tags: AYTU Viatris Investor Conferences Healthcare Aytu BioPharma fiscal 2026 Q2 results conference call financial results
Last updated: Jan 28, 2026